Myopericarditis After COVID-19 mRNA Vaccination

Shintaro Sakaguchi, MD; Naoki Fujimoto, MD, PhD;
Kazuhide Ichikawa, MD, PhD; Daisuke Izumi, MD;
Koji Katsuta, MD, PhD; Masafumi Takafuji, MD;
Kyoko Imanaka-Yoshida, MD, PhD;
Kaoru Dohi, MD, PhD

A previously healthy 49-year-old man presented to hospital 11 days after a 2nd dose of the BNT162b2-mRNA (Pfizer-BioNTech) vaccine for essential workers. He began to notice fever, appetite loss, cough, and orthopnea 4 days after vaccination. Oral nonsteroidal anti-inflammatory drug and antibiotics for several days failed to relieve his symptoms. On admission, physical examination revealed fever of 37.3°C, blood pressure of 95/67 mmHg, pulse of 93 beats/min and pericardial friction rub on auscultation. ECG demonstrated low voltage in the limb leads and poor R waves in V1–2. Chest X-ray showed mild congestion (**Figure A**). Laboratory evaluation showed elevated B-type natriuretic peptide of 1,113.0 pg/mL, troponin I of 4,364.5 pg/mL, and C-reactive protein of 19.78 mg/mL. Blood cell count was normal with no peripheral eosinophilia. Nasopharyngeal SARS CoV-2 antigen and other viral studies were negative. Cardiac magnetic resonance imaging (CMR) showed diffuse myocardial edema on T2-weighted imaging (**Figure B**), reduced left ventricular ejection fraction of 33%, diffuse late gadolinium enhancement (LGE), and increased global native T1 value of 1,301 ms (**Figure C**). Endomyocardial biopsy revealed diffuse lymphocytic infiltrates and some eosinophils (**Figure D**), confirming the diagnosis of myocar-

ditis. Oral diuretics and aspirin relieved his symptoms. CMR on day 12 showed resolution of the myocardial edema (**Figure E**), decrease in the native T1 value to 1,176 ms (**Figure F**), and partial LGE. He was discharged home on day 15.

To our knowledge, this is the first case of presumed COVID-19 vaccine-related myocarditis diagnosed by myocardial biopsy and CMR in a middle-aged man. Although myocarditis following COVID-19 vaccine can be mild and occur in the young,¹ more intense myocarditis might occur in individuals of any age. Thus, careful attention to myocarditis is necessary.

Disclosure

K.I.-Y. received an independent medical educational grant >1,000,000 yen from Pfizer Japan Inc.

Reference

1. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. *JAMA Cardiol* 2021; e212833. doi:10.1001/jamacardio.2021.2833.

Received August 2, 2021; revised manuscript received August 10, 2021; accepted August 12, 2021; J-STAGE Advance Publication released online September 30, 2021 Time for primary review: 6 days

Department of Cardiology (S.S., K.I., D.I.), Department of Pathology (K.K.), Matsusaka Municipal Hospital, Matsusaka; Department of Cardiology and Nephrology (N.F., K.D.), Department of Radiology (M.T.), Department of Pathology and Matrix Biology (K.I.-Y.), Mie Universal Graduate School of Medicine, Tsu, Japan
Mailing address: Naoki Fujimoto, MD, PhD, Department of Cardiology and Nephrology, Mie Universal Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan. E-mail: naokifujimo@clin.medic.mie-u.ac.jp

All rights are reserved to the Japanese Circulation Society.

For permissions, please e-mail: cj@j-circ.or.jp

ISSN-1346-9843

Figure. Chest X-ray (**A**), T2-weighted cardiac magnetic resonance imaging (CMR) (**B**), native T1 mapping (**C**) on admission. Histology (H&E) (**D**). Repeated T2-weighted CMR (**E**) and native T1 mapping (**F**) on day 12. LVEF, left ventricular ejection fraction.